Printer Friendly

Inovio announces results of pre-clinical study of Lassa fever vaccine.

Inovio Pharmaceuticals announced results of a study in which a DNA vaccine provided 100% protection for non-human primates challenged with a lethal dose of the Lassa fever virus. These results were published in the most recent issue of Human Vaccines & Immunotherapeutics in an article entitled, "A DNA Vaccine Delivered by Dermal Electroporation Fully Protects Cynomolgus Macaques Against Lassa Fever," by Inovio researchers and U.S. Army collaborators. In the study, funded by a previously awarded $3.5M grant from the National Institute of Allergy and Infectious Diseases, the animals first received Inovio's DNA vaccine against Lassa hemorrhagic fever via intradermal administration with CELLECTRA delivery device. The animals were then challenged with a lethal dose of the Lassa virus. "All of the animals survived; in fact, none of the vaccinated animals displayed any signs of disease," the company stated.

COPYRIGHT 2017 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Article Type:Clinical report
Date:Oct 24, 2017
Previous Article:Treasury Market Outlook: bond yields are sharply higher.
Next Article:Waddell & Reed cuts dividend to 25c from 46c, announces $250M buyback.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |